new glp 1 agonist GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Possible mechanisms of action of

A "normal" LDL-C or a low 10-year risk score is not the same as no risk

Based on the abovementioned clinical issues, it is imperative to investigate the molecular mechanism underlying the onset and progression of CKD to identify novel therapeutic targets

In phase 3 research, a gradual escalation over roughly 16 weeks to the maintenance dose of 2.4 mg was chosen to optimise tolerability NEJM, 2025

Neuroscientific studies have explored BPC-157s involvement in neural recovery pathways

Now, in the 1970s and early eighties, some scientists had noticed that if animals got stung or bit by certain venomous creatures, the victim's pancreas would start secreting all kinds of hormones